SCHEMBL5062829

SCHEMBL5062829

O=C(O)c1ccc2c(c1)NC(=O)c1ccc(F)cc1S2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 6/20 0.57
▸ MAPT P10636 5/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ RXFP1 Q9HBX9 2/20 0.57
▸ HPGD P15428 1/20 0.50
▸ HTT P42858 1/20 0.47
▸ POLB P06746 5/20 0.45
▸ L3MBTL1 Q9Y468 4/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ THRB P10828 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ BACE1 P56817 1/20 0.42
▸ GAA P10253 2/20 0.41
▸ NOX1 Q9Y5S8 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ CYBB P04839 1/20 0.41
▸ APP P05067 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ SNCA P37840 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30186428 0.91 TP53 (0.58) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL5057271 0.91 TP53 (0.58) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL23094972 0.90 HPGD (0.55) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL29441686 0.85 HPGD (0.51) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL17085845 0.85 HPGD (0.51) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL5064794 0.84 HPGD (0.50) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL17086128 0.84 TP53 (0.57) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL4670438 0.82 HPGD (0.70) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL29441734 0.81 TP53 (0.59) TP53MAPTSMN1; SMN2RXFP1HPGD
SCHEMBL17085962 0.81 TP53 (0.59) TP53MAPTSMN1; SMN2RXFP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2023-02-09 — — US disclosed
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2023-02-09 — — US disclosed
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-01-19 — — US disclosed
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-01-19 — — US disclosed
US-20180258084-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2018-09-13 — — US disclosed
WO-2017048950-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2017-03-23 — — WO disclosed
US-20170015658-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2017-01-19 — — US disclosed
US-20170015658-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2017-01-19 — — US disclosed
WO-2015138895-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-09-17 — — WO disclosed
WO-2009075691-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2009-06-18 — — WO disclosed
WO-2008118141-A2 USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY ACADIA PHARMACEUTICALS INC. (US) 2008-10-02 — — WO disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 — — US disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 — — US disclosed
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170015658-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS HAVCR2, MAVS, FABP1 TP53 602/4885MAPT 2680/4885SMN1; SMN2 4496/4885
US-20230019129-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS HAVCR2, MAVS, FABP1 TP53 602/4885MAPT 2680/4885SMN1; SMN2 4496/4885
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS TP53 411/4885MAPT 2896/4885SMN1; SMN2 4557/4885
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS TP53 411/4885MAPT 2896/4885SMN1; SMN2 4557/4885
US-11814376-B2 Hepatitis b core protein modulators HAVCR2, FABP1, MAVS TP53 411/4885MAPT 2896/4885SMN1; SMN2 4557/4885
US-20180258084-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS TP53 411/4885MAPT 2896/4885SMN1; SMN2 4557/4885
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE CNR1, CNR2, FAAH TP53 4870/4885MAPT 3344/4885SMN1; SMN2 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback